NCT06278350
Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate-to-Severe Plaque Psoriasis
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate-to-Severe Plaque Psoriasis
InventisBio Co., Ltd·Phase 2·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- Plaque Psoriasis
- Drug/Device/Intervention
- D-2570
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- InventisBio Co., Ltd
- Location
- Beijing, China
Timeline & enrollment
- Phase
- Phase 2
- Start date
- Feb 04, 2024
- End date
- Mar 31, 2025
- Enrollment
- 160 participants
Primary outcome
Percentage of subjects with at least 75% improvement in PASI
Summary
This is a randomized, double-blind, placebo-controlled, multicenter clinical trial in
 participants with moderate-to-severe plaque psoriasis .
ICD-10 classifications
PsoriasisLarge plaque parapsoriasisOther psoriasisSmall plaque parapsoriasisArthropathic psoriasis
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06278350
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT06278350 through Pure Global AI's free database. This Phase 2 trial is sponsored by InventisBio Co., Ltd and is currently Recruiting. The study focuses on Plaque Psoriasis. Target enrollment is 160 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.